Evaluation of Antiviral Activity of Ivermectin against Infectious Bovine Rhinotracheitis Virus in Rabbit Model.
bovine herpes virus 1(BoHV-1)
infectious bovine rhinotracheitis
infectious bovine rhinotracheitis virus (IBRV)
ivermectin
rabbits
treatment
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
24
08
2023
revised:
27
09
2023
accepted:
03
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Infectious bovine rhinotracheitis (IBR) caused by bovine herpes virus 1 (BoHV-1) can lead to enormous economic losses in the cattle industry. Vaccine immunization is preferentially used to decrease its transmission speed and resultant clinical signs, rather than to completely stop viral infection. Therefore, a drug effective in treating IBR is urgently needed. Our previous work demonstrated that ivermectin significantly inhibited viral replication in a cell infection model. This study aimed to investigate its antiviral effects in vivo by using a rabbit infection model. The viral inhibition assay was first used to confirm that ivermectin at low concentrations (6-25 nM) could reduce viral titers (TCID
Identifiants
pubmed: 37893888
pii: ani13203164
doi: 10.3390/ani13203164
pmc: PMC10603647
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Key Research and Development Program of the Ningxia Hui Autonomous Region
ID : (#2021BEF02028)
Organisme : Chinese Agricultural Research System of MOF and MARA
ID : (CARS-37)
Références
Virus Res. 2021 May;297:198384
pubmed: 33713753
Vet Microbiol. 2002 Apr 22;86(1-2):139-55
pubmed: 11888697
J Pharm Pharm Sci. 2020;23:462-469
pubmed: 33227231
Immunol Rev. 2012 Jan;245(1):189-208
pubmed: 22168421
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
J Control Release. 2021 Jan 10;329:758-761
pubmed: 33038449
Viral Immunol. 2011 Aug;24(4):331-9
pubmed: 21830904
J Vet Pharmacol Ther. 1997 Apr;20(2):91-9
pubmed: 9131534
Virol Sin. 2013 Feb;28(1):36-42
pubmed: 23385353
Microorganisms. 2020 Mar 13;8(3):
pubmed: 32183205
Clin Pharmacol Ther. 2020 Oct;108(4):762-765
pubmed: 32378737
Microb Pathog. 2021 Jun;155:104914
pubmed: 33915205
Virus Res. 2014 Jun 24;185:72-6
pubmed: 24657787
J Vet Pharmacol Ther. 2003 Oct;26(5):343-8
pubmed: 14633186
J Antibiot (Tokyo). 2023 Aug;76(8):481-488
pubmed: 37185581
Arch Virol. 2016 Feb;161(2):257-68
pubmed: 26518309
J Virol Methods. 2008 Jun;150(1-2):77-9
pubmed: 18423632
J Antibiot (Tokyo). 2020 Sep;73(9):593-602
pubmed: 32533071
Res Vet Sci. 2013 Oct;95(2):709-16
pubmed: 23602434
J Neurovirol. 2007 Aug;13(4):384-8
pubmed: 17849322
Antiviral Res. 2018 Nov;159:55-62
pubmed: 30266338
Lab Anim. 2010 Apr;44(2):138-42
pubmed: 19959569
Vaccine. 2014 Sep 3;32(39):4909-15
pubmed: 25066735
J Virol. 2000 Jun;74(11):5337-46
pubmed: 10799611
Vaccine. 2021 Feb 5;39(6):1007-1017
pubmed: 33446386
Transbound Emerg Dis. 2021 Mar;68(2):587-597
pubmed: 32643286